tides
Oligonucleotides
EUROAPI is able to accompany a wide client base across the whole oligonucleotide development continuum, from research to commercialization.
On November 21, 2023, EUROAPI acquired BianoGMP (“Biano”), an oligonucleotide CDMO player focused on small-scale, early-stage (pre-clinical to phase 1), complex and customized projects.
By coupling Biano’s expertise and capacity in early-stage projects with EUROAPI’s larger scale capabilities, EUROAPI aims to support its clients along the drug development pathway as a one-stop shop.
EUROAPI can work on all Oligonucleotide project phases from early drug development to commercial production:
High quality preclinical oligo-nucleotides for your lead identification, optimization and tox-studies.
Extensive experience in modifications, challenging and ligation chemistries.
Best in class analytics for oligonucleotide based drugs.
Analytical method development, optimization and validation depending on your needs and clinical stage.
GMP oligonucleotide production for personalized medicine (e.g. single-subject “N of 1” treatments) and initial clinical studies.
Attractive timelines and costs enable early projects to step into clinical development.
Your partner for the scale you require by providing efficient upscaling of synthesis and downstream process into kg-scale and commercial batch production.
Efficient and transparent project management – from design phase until final document delivery.
Experienced project teams guarantee timelines as well as product and document quality.
Adequate quality system for your clinical batch with extensive experience in customer-, FDA- and EMA authority inspections.
